# FST

## Overview
The FST gene encodes follistatin, a multifunctional glycoprotein that plays a pivotal role in modulating the activity of the transforming growth factor-beta (TGF-β) superfamily, particularly through its high-affinity binding to activin. Follistatin acts as an antagonist to activin, thereby regulating various physiological processes, including reproductive hormone secretion and muscle growth. The protein is characterized by its cysteine-rich domains, which facilitate its interaction with TGF-β ligands, and exists in multiple isoforms, primarily FST315 and FST288, resulting from alternative splicing. These isoforms differ in their distribution and functional roles, with FST315 being the predominant circulating form and FST288 more localized due to its affinity for cell surface proteoglycans. Follistatin's ability to neutralize activin and other TGF-β family members underscores its significance in maintaining homeostasis and its potential implications in various pathological conditions, such as amyotrophic lateral sclerosis and polycystic ovary syndrome (Blount2008A; FahmyGarcia2019Follistatin; Shtilbans2011Differential).

## Structure
The FST gene encodes follistatin, a glycoprotein involved in binding and neutralizing members of the TGF-beta superfamily, such as activin. The primary structure of follistatin includes multiple isoforms, primarily FST315 and FST288, resulting from alternative splicing. FST315 is the longer isoform, consisting of 315 amino acids, while FST288 consists of 288 amino acids (FahmyGarcia2019Follistatin).

Follistatin's secondary structure is characterized by several cysteine-rich domains, which include epidermal growth factor-like and kazal serine protease inhibitor-like subdomains. These domains are crucial for the protein's ability to wrap around TGF-beta ligands and block receptor binding sites (Sosa2024The). The tertiary structure of follistatin is compact and globular, with the FSD1 and FSD2 domains playing significant roles in ligand binding, particularly with activin and myostatin (Cash2009The; Schneyer2008Differential).

Post-translational modifications of follistatin include glycosylation at three putative sites, which influences its stability and secretion. The glycosylation patterns differ between secreted and intracellular forms, affecting the protein's pharmacokinetic properties (Sosa2024The). The quaternary structure involves the formation of a 2:1 follistatin-ligand complex, particularly with activin, enhancing its neutralizing capability (Sosa2024The).

## Function
Follistatin (FST) is a glycoprotein that plays a critical role in regulating activin signaling, a member of the transforming growth factor-beta (TGF-β) superfamily, by binding to and neutralizing activin with high affinity (Blount2008A; Liu2012Mutational). This interaction occurs at a 2:1 molar ratio, effectively modulating activin's biological activity and maintaining a balance crucial for normal physiological functions, such as the regulation of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) production during the estrus cycle (Blount2008A). Follistatin is expressed in various tissues, including the adrenal cortex, ovary, pancreas, and pituitary, where it acts as a local buffer to modulate the bioactivity of activins and other TGF-β family ligands (Blount2008A; Liu2012Mutational).

The FST gene produces two alternatively spliced mRNA transcripts, resulting in two protein isoforms: FS315 and FS288. FS315 is the predominant circulating form, while FS288, which lacks a C-terminal tail, is more localized, associating with cell surface proteoglycans to modulate activin signaling locally (Blount2008A). Follistatin's role in regulating activin is critical for follicle development and maturation, impacting fertility and ovarian function (Kimura2009The).

## Clinical Significance
Follistatin (FST) has been implicated in several diseases and conditions due to alterations in its expression levels. In amyotrophic lateral sclerosis (ALS), FST is overexpressed compared to healthy controls, suggesting a potential role in the disease's pathology. This overexpression was confirmed through RT-PCR analysis, although protein level analysis was inconclusive due to non-specific bands (Shtilbans2011Differential). The study highlights the complexity of differential gene expression in ALS, noting that variability in muscle sample sources can affect gene expression patterns (Shtilbans2011Differential).

FST is also associated with conditions like polycystic ovary syndrome (PCOS), muscle wasting diseases, and certain cancers, where its altered expression can impact tissue repair and metabolic processes. Dysregulation of FST can lead to significant clinical outcomes, affecting muscle growth and inflammation. The gene's role in binding and inhibiting activins is crucial in these processes, and its dysregulation can contribute to the pathophysiology of these conditions. However, specific mutations in the FST gene and their direct link to diseases are not detailed in the provided context, indicating a need for further research to elucidate these connections.

## Interactions
Follistatin (FST) is a protein that interacts with various members of the transforming growth factor-β (TGF-β) superfamily, including activins, myostatin, and bone morphogenetic proteins (BMPs). FST binds to activin with high affinity, forming a complex that inhibits activin's ability to interact with its type I and type II receptors, thereby blocking its signaling pathways (Thompson2005The; Harrington2006Structural). The interaction involves FST wrapping around the activin dimer, with two FST molecules encircling the activin, covering significant portions of its surface and receptor binding sites (Thompson2005The; Lerch2007Structural).

FST exists in multiple isoforms, including FS288 and FS315, which differ in their binding affinities and interactions. FS288 has a higher affinity for heparan sulfate proteoglycans on cell surfaces, allowing it to effectively trap activin in the extracellular matrix, while FS315 is more soluble and found in serum (Sugino1993Molecular; Lerch2007Structural). These isoforms also differ in their interactions with heparin, with FS288 showing greater affinity, which influences their localization and physiological roles (Lerch2007Structural). The binding of FST to activin and other TGF-β family members is crucial for regulating various biological processes, including muscle growth and development (Sidis2006Biological).


## References


[1. (Liu2012Mutational) L. Liu, R. Tan, J. Liu, Y. Cui, J. Liu, and J. Wu. Mutational analysis of thefstgene in chinese women with idiopathic premature ovarian failure. Climacteric, 16(4):469–472, November 2012. URL: http://dx.doi.org/10.3109/13697137.2012.733982, doi:10.3109/13697137.2012.733982. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3109/13697137.2012.733982)

[2. (Kimura2009The) Fuminori Kimura, Yisrael Sidis, Lara Bonomi, Yin Xia, and Alan Schneyer. The follistatin-288 isoform alone is sufficient for survival but not for normal fertility in mice. Endocrinology, 151(3):1310–1319, December 2009. URL: http://dx.doi.org/10.1210/en.2009-1176, doi:10.1210/en.2009-1176. This article has 37 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1210/en.2009-1176)

[3. (Harrington2006Structural) Adrian E Harrington, Samantha A Morris-Triggs, Brandon T Ruotolo, Carol V Robinson, Shin-ichi Ohnuma, and Marko Hyvönen. Structural basis for the inhibition of activin signalling by follistatin. The EMBO Journal, 25(5):1035–1045, February 2006. URL: http://dx.doi.org/10.1038/sj.emboj.7601000, doi:10.1038/sj.emboj.7601000. This article has 126 citations.](https://doi.org/10.1038/sj.emboj.7601000)

[4. (Cash2009The) Jennifer N Cash, Carlis A Rejon, Alexandra C McPherron, Daniel J Bernard, and Thomas B Thompson. The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding. The EMBO Journal, 28(17):2662–2676, July 2009. URL: http://dx.doi.org/10.1038/emboj.2009.205, doi:10.1038/emboj.2009.205. This article has 131 citations.](https://doi.org/10.1038/emboj.2009.205)

[5. (Schneyer2008Differential) Alan L. Schneyer, Yisrael Sidis, Anisha Gulati, Jie L. Sun, Henry Keutmann, and Philip A. Krasney. Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin. Endocrinology, 149(9):4589–4595, June 2008. URL: http://dx.doi.org/10.1210/en.2008-0259, doi:10.1210/en.2008-0259. This article has 67 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1210/en.2008-0259)

[6. (Sugino1993Molecular) K. Sugino, N. Kurosawa, T. Nakamura, K. Takio, S. Shimasaki, N. Ling, K. Titani, and H. Sugino. Molecular heterogeneity of follistatin, an activin-binding protein. higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell. Journal of Biological Chemistry, 268(21):15579–15587, July 1993. URL: http://dx.doi.org/10.1016/s0021-9258(18)82296-7, doi:10.1016/s0021-9258(18)82296-7. This article has 161 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(18)82296-7)

[7. (Shtilbans2011Differential) Alexander Shtilbans, Soon-Gang Choi, Mary E. Fowkes, Greg Khitrov, Mona Shahbazi, Jess Ting, Weijia Zhang, Yezhou Sun, Stuart C. Sealfon, and Dale J. Lange. Differential gene expression in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis, 12(4):250–256, March 2011. URL: http://dx.doi.org/10.3109/17482968.2011.560946, doi:10.3109/17482968.2011.560946. This article has 20 citations.](https://doi.org/10.3109/17482968.2011.560946)

[8. (Sosa2024The) Jennifer Sosa, Akinsola Oyelakin, and Satrajit Sinha. The reign of follistatin in tumors and their microenvironment: implications for drug resistance. Biology, 13(2):130, February 2024. URL: http://dx.doi.org/10.3390/biology13020130, doi:10.3390/biology13020130. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/biology13020130)

[9. (Sidis2006Biological) Yisrael Sidis, Abir Mukherjee, Henry Keutmann, Anne Delbaere, Miyuki Sadatsuki, and Alan Schneyer. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology, 147(7):3586–3597, July 2006. URL: http://dx.doi.org/10.1210/en.2006-0089, doi:10.1210/en.2006-0089. This article has 178 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1210/en.2006-0089)

[10. (Blount2008A) Amy L. Blount, Joan M. Vaughan, Wylie W. Vale, and Louise M. Bilezikjian. A smad-binding element in intron 1 participates in activin-dependent regulation of the follistatin gene. Journal of Biological Chemistry, 283(11):7016–7026, March 2008. URL: http://dx.doi.org/10.1074/jbc.m709502200, doi:10.1074/jbc.m709502200. This article has 27 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m709502200)

[11. (Thompson2005The) Thomas B. Thompson, Thomas F. Lerch, Robert W. Cook, Teresa K. Woodruff, and Theodore S. Jardetzky. The structure of the follistatin:activin complex reveals antagonism of both type i and type ii receptor binding. Developmental Cell, 9(4):535–543, October 2005. URL: http://dx.doi.org/10.1016/j.devcel.2005.09.008, doi:10.1016/j.devcel.2005.09.008. This article has 232 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.devcel.2005.09.008)

[12. (Lerch2007Structural) Thomas F. Lerch, Shunichi Shimasaki, Teresa K. Woodruff, and Theodore S. Jardetzky. Structural and biophysical coupling of heparin and activin binding to follistatin isoform functions. Journal of Biological Chemistry, 282(21):15930–15939, May 2007. URL: http://dx.doi.org/10.1074/jbc.m700737200, doi:10.1074/jbc.m700737200. This article has 53 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m700737200)

[13. (FahmyGarcia2019Follistatin) Shorouk Fahmy-Garcia, Eric Farrell, Janneke Witte-Bouma, Iris Robbesom-van den Berge, Melva Suarez, Didem Mumcuoglu, Heike Walles, Sebastiaan G. J. M. Kluijtmans, Bram C. J. van der Eerden, Gerjo J. V. M. van Osch, Johannes P. T. M. van Leeuwen, and Marjolein van Driel. Follistatin effects in migration, vascularization, and osteogenesis in vitro and bone repair in vivo. Frontiers in Bioengineering and Biotechnology, March 2019. URL: http://dx.doi.org/10.3389/fbioe.2019.00038, doi:10.3389/fbioe.2019.00038. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fbioe.2019.00038)